Top Markets
Coin of the day
Jiangsu Recbio Technology Co., Ltd. Jiangsu Recbio Technology Co., Ltd.

Jiangsu Recbio Technology Co., Ltd.

2179
Hisse Senetlerindeki Sıralama #15662
Jiangsu Recbio Technology Co., Ltd. operates as a biotechnology company... Jiangsu Recbio Technology Co., Ltd. operates as a biotechnology company primarily engaged in the pioneering research, development, and eventual market introduction of subunit vaccines throughout the People's Republic of China. A significant portion of its pipeline is dedicated to combating human papillomavirus (HPV)-related diseases, including cervical cancer and genital warts. Its most advanced candidate, REC603, is a recombinant 9-valent HPV vaccine currently undergoing Phase III clinical trials. Additionally, two bivalent HPV vaccines, REC601 and REC602, are progressing through Phase I trials. Further early-stage development includes the quadrivalent REC604a and 9-valent REC604b recombinant HPV vaccines, both in preclinical stages. Beyond HPV, the company boasts a diverse pipeline addressing other infectious diseases. Its COVID-19 efforts include ReCOV, a recombinant vaccine candidate in Phase II/III trials, and the preclinical messenger RNA (mRNA) candidate, R520A. Other preclinical projects target various conditions, such as the recombinant shingles vaccine REC610, the virus-vectored adult tuberculosis vaccine REC607, and its recombinant counterpart REC606. Also in preclinical development are the recombinant quadrivalent influenza vaccine REC617 and the recombinant quadrivalent hand-foot-mouth disease vaccine REC605. Established in 2011, Recbio Technology maintains its headquarters in Taizhou, People's Republic of China.
Hisse Fiyatı
$0.63963115
Son senkronizasyon: 2026-08-26
Piyasa Değeri
$339.16M
Değişim (1 gün)
0.00%
Değişim (1 yıl)
-35.23%
Ülke
CN
Ticaret Jiangsu Recbio Technology Co., Ltd. (2179)

Kategori

Jiangsu Recbio Technology Co., Ltd. (2179) için gelir
Sep 2026 itibarıyla gelir TTM: 0
Jiangsu Recbio Technology Co., Ltd. şirketinin en son finansal raporlarına göre, mevcut geliri (TTM) 0'dir. 2026 yılında şirketin geliri 0 önceki yıla eşit 2026 yılındaki 0 gelirine göre. Gelir, bir şirketin mal veya hizmet satışından elde ettiği toplam tutardır. Kazançtan farklı olarak, hiçbir gider düşülmez.
Jiangsu Recbio Technology Co., Ltd. için 2026 ile 2026 arasındaki gelir geçmişi
Her yılın sonunda gelir
Yıl Gelir Değiştir
Sağlanan tarihler için yeterli veri yok.
Benzer şirketler veya rakiplerin geliri
Şirket Gelir Gelir Farkı Ülke
$12.62B -
US
$6.02B -
NL
$2.23B -
US
$15.74B -
AU
- -
CH